Adapt Pharma announced the availability of Narcan Nasal Spray (naloxone HCl) for the emergency reversal of known or suspected opioid overdose, including respiratory and/or central nervous system (CNS) depression.
Narcan Nasal Spray, the first naloxone nasal spray, was approved in November 2015 by the Food and Drug Administration. Naloxone HCl is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites. It reverses the effects of opioids, including respiratory depression, sedation, and hypotension.
In partnership with the Clinton Health Matters Initiative, the company will offer a free carton of Narcan Nasal Spray to all high schools in the U.S. It is also available to order through various wholesalers, on the direct product website, and through select specialty distributors.
Narcan Nasal Spray is available as 4mg single-dose sprays in 2-count packs.
For more information call (844) 462-7226 or visit NarcanNasalSpray.com.